The initial reviews of the US Food and Drug Administration's remodel of the advisory committee briefing document seemed largely favorable, although there were calls to include more information in some cases.
Merck, ODAC Mostly Like US FDA's Point-Counterpoint Briefing Document
Tweaks to the combined advisory committee briefing document such as appendices with quality of life or other commonly requested information may be needed.
